Trial Profile
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2013
Price :
$35
*
At a glance
- Drugs Tesofensine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ADVANS
- 28 Oct 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00148512).
- 05 Nov 2010 New trial record.